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Introduction Carbamazepine is an anticonvulsant that is FDA-approved to treat bipolar 
I disorder, epilepsy, glossopharangeal neuralgia, and trigeminal neuralgia, and also has 
expansive non-labeled indications. On January 12, 2007, the FDA released an alert 
stating that carbamazepine can cause dangerous, or even fatal, skin reactions (Stevens 
Johnson Syndrome and Toxic Epidermal Necrolysis), most commonly in patients with a 
particular human leukocyte antigen (HLA) allele variation HLA-B*1502. This allele 
occurs almost exclusively in patients with Han Chinese ancestry, but also is found in 
South Asian Indians. Toxic reactions may occur up to 3-6 months after starting 
carbamazepine. Genetic tests for HLA-B*1502 are available, but Mission Neurology and 
Mission Hospital currently do not administer these tests prior to carbamazepine use.	  	   
 
Purpose The purpose of the study was to characterize the use of carbamazepine at 
Mission Neurology; and with Mission Neurology physicians, develop and evaluate 
different approaches to minimize use of carbamazepine in at risk populations. 
Especially of interest is the frequency in which Asian patients have received 
carbamazepine as outpatients (Mission Neurology Clinic) and as inpatients at Mission 
Hospital.  
 
Methods An electronic chart review of patients who received carbamazepine at Mission 
Neurology outpatient clinic and inpatient at Mission Hospital (including ED) between 
2008 and 2014 was conducted. The initial search query included the following clinical 
and demographic variables to characterize carbamazepine use: date of visit, date 
prescribed carbamazepine, clinic location, primary health insurance plan, race or 
ethnicity, sex, age, ICD9 diagnosis code, allergies, other medications, and ICD9 codes 
associated with adverse drug events.  
 
Results The reviewed medical records from Mission Neurology revealed that a total of 
180 patients were prescribed carbamazepine, with 165 Caucasian, 2 American Indian, 1 
Asian, 1 African American, and 11 patients of unknown ancestry.  At Mission Hospital a 
total of 2,407 individual patients were administered carbamazepine as an in-patient. Of 
those patients, 1,823 were Caucasian, 105 African American, 17 American Indian, 4 
Pacific Islander, 4 Asian, and 449 patients were of unknown ancestry.  Between 2008 
and 2014 at Mission Hospital, there were 72 incidences of erythema multiforme rash, 
SJS, or TEN, in 62 unique patients. 
 
Conclusion This data demonstrates that at-risk patients, due to their ancestry, have 
received carbamazepine at Mission Health between 2008 and 2014. This data supports 
the consideration of a policy change to require testing before carbamazepine is 












Carbamazepine is an anticonvulsant medication that approved by the U.S Food and 
Drug Administration (FDA) to treat bipolar I disorder, epilepsy, glossopharangeal 
neuralgia, and trigeminal neuralgia, and also has expansive non-labeled indications. On 
January 12, 2007, the FDA released an alert stating that carbamazepine can cause 
dangerous, or even fatal, skin reactions (Stevens Johnson Syndrome and Toxic 
Epidermal Necrolysis), most commonly in patients with a particular human leukocyte 
antigen (HLA) allele variation HLA-B*1502. This allele occurs almost exclusively in 
patients with Han Chinese ancestry, but also is found in South Asian Indians. Toxic 
reactions may occur up to 3-6 months after starting carbamazepine. Genetic tests for 
HLA-B*1502 are available, but Mission Neurology and Mission Hospital currently do not 
administer these tests prior to carbamazepine use.	  	  The purpose of the study was to 
characterize the use of carbamazepine at Mission Neurology; and with Mission 
Neurology physicians, develop and evaluate different approaches to minimize use of 
carbamazepine in at risk populations. 
 
Carbamazepine FDA Black Box Warning 
On January 12, 2007, the FDA released an alert stating that carbamazepine can cause 
dangerous or even fatal skin reactions (Stevens-Johnson Syndrome and Toxic 
Epidermal Necrolysis).1 Up to one in 1000 patients treated with epileptic drugs will 
experience one of these reactions.2 There is known cross reactivity between different 
epileptic drugs, but the mechanism of the cross reactivity has not been elucidated.  
Studies have shown that there are associations between human leukocyte antigen 
(HLA) alleles and carbamazepine, lamotrigine, and phenytoin-induced Stevens-Johnson 
Syndrome.3 
The FDA issues black box warnings to be featured in the labeling of drugs associated 
with serious adverse reactions. Reactions are identified through the Adverse Event 
Reporting System and the Office of Surveillance and Epidemiology, which evaluate post 
market safety findings. Black box warnings are highly publicized, yet the drugs involved 
remain viable treatment options, and it is up to physician to decide when the benefit of 
treatment outweighs the risk of the adverse reactions.4  
For carbamazepine, and the warning in discussion, the FDA states their reasoning: “In 
the Caucasian population, the risk of developing a subcutaneous skin reaction is 1-6 per 
10,000 patients. But in the Asian population, the risk is 10-fold higher and tends to be 
associated with a specific allele HLA-B*1502.” Also in Asians who developed SJS/TEN 
with carbamazepine, 98% of the patients carry an HLA-B*1502 allele.5 This boxed 
warning takes into account this information, giving physicians an opportunity to use 
clinical judgment to make the best decision for at-risk patients.   
Carbamazepine’s labeled indications for use are partial seizures with complex 
symptomatology (psychomotor, temporal lobe), generalized tonic-clonic seizures (grand 
mal), mixed seizure patterns, trigeminal neuralgia, glossopharyngeal neuralgia, and 
acute manic or mixed episodes associated with bipolar 1 disorder. Restless leg 
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syndrome can be treated with carbamazepine as well, but the use is unlabeled.6 The 
drug, manufactured by Novartis, is commonly used for many indications, posting 400 
million dollars in sales in 2007, alone.   
Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are serious, 
blistering, cutaneous adverse drug reactions with poor outcomes and mortality rates of 
up to 1-5% and 25-35%, respectively.7 SJS is characterized by epidermal detachment 
affecting up to 10% of the body surface area, whereas TEN usually involves >30% of 
the body surface area. Mission Health triages patients with SJS/TEN, eventually having 
to send to outside hospitals with burn units.   
 
The FDA currently recommends that “patients with ancestry in at-risk populations 
should be screened for the presence of HLA-B*15:02 allele prior to starting 
carbamazepine.”	  The genetic test for HLA-B*15:02 test is available in the US. The test 
requires either 7mL of whole blood or four buccal swab, and costs about $330. There is 
also a significant cost associated with the treatment of SJS/TEN, which in the case of 
Mission Health involves the need to pay travel and medical expenses to safely transfer 
the patient to the nearest burn center, which is about two hours away at Wake Forest 
Medical Center. By developing a protocol for pre-carbamazepine genotype testing 
and/or developing a policy to offer alternative therapies at Mission Health to patients of 
Asian/Indian descent, these debilitating adverse reactions could be avoided or at least 
minimized, which would improve patient safety and reduce costs.   
Pharmacogenomics  
Pharmacogenomics is the science of identifying how specific human gene variations 
can be used to predict drug response in individual patients. Thus, by knowing genetic 
information, clinicians may be better able to predict drug response; including minimizing 
potentially toxic side effects and maximizing dosing effectiveness.8 Figure 1 illustrates 
these principles. The field is currently limited to about 28 non-oncololytic drug-gene 
associations, mostly regarding drug metabolism and adverse events.  
Figure 1: Pharmacogenomics Illustration – Courtesy of H. Mcleod 
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Human Leukocyte Antigen Allele, HLA-B*1502 
The HLA gene family codes for a group of proteins that make up the human leukocyte 
antigen complex. This complex acts within the immune system to distinguish the body’s 
own proteins from foreign proteins. HLA-B genes are specifically located on the short 
arm of chromosome 6 (6p21.3). HLA-B genes code for proteins that distinguish 
intracellular antigens as self or foreign, non-self proteins. The HLA-B complex carries 
fragments of the foreign proteins to the surface of the cell, to flag for destruction by the 
immune system. Thus, triggering an immune response.9 
Carbamazepine-induced SJS/TEN reactions are T cell-mediated, delayed-type drug 
hypersensitivity reactions. SJS/TEN lesions are induced by the migration of circulating 
skin-homing cytotoxic T lymphocytes that are activated, proliferate, and release 
cytotoxic proteins to induce keratinocyte apoptosis. A direct interaction between HLA-
B*1502 and carbamazepine has been shown to activate these cytotoxic T lymphocytes, 
leading to drug-induced SJS/TEN reactions.10 
In the case of carbamazepine, SJS and TEN are significantly more common in patients 
with a particular HLA allele, HLA-B*1502. This allele occurs almost exclusively in 
patients with ancestry across broad areas of Asia, especially those of Han Chinese 
ancestry but also including South Asian Indians.11 Table 1 lists specific populations and 
calculated HLA-B*1502 allele frequencies.   
Table 1: Population Frequency of HLA-B*150211 
Continent Ethnicity Allele Frequency (%) 
North America Asian 5.1 
 African 0.2 
 European 0 
 Hispanic  0 
Asia Korean 0.5 
 Han Chinese 10.2 
 Singapore 11.6 
 Malay 8.4 
 Thai 6.1 
 Filipino 5.3 
 India Mumbai Marathas 1 
 India North Hindi 2 
 India Khandesh Pawra 6 
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HLA-A*3101 has also been associated with carbamazepine hypersensitivities, including 
SJS/TEN, maculopapular exanthema (MPE), and DRESS (drug reactions with 
eosinophilia and systemic symptoms).  Of interest is that this allele is associated with a 
wider range of ethnicities, including, not only Han Chinese, but also those of Japanese, 
South Korean, and Caucasian descent. HLA-A*3101 more commonly leads to 
subcutaneous skin reactions. Although when looking at specifically SJS/TEN, which are 
more severe subcutaneous skin reactions, HLA-B*1502 has a stronger association, thus 
why it is the focus of this study.11  
In 2013, the Clinical Pharmacogenetics Implementation Consortium (CPIC), a group 
formed as a shared project between PharmGKB and the Pharmacogenomics Research 
Network, released guidelines to help clinicians understand how genetic test results 
should be used to optimize the use of carbamazepine in at-risk populations. Genetic 
tests for HLA-B*1502 are available through commercial lab testing companies, and 
patients with ancestry from areas in which this genotype is present should be screened 
for the allele before starting treatment for carbamazepine. CPIC guidelines recommend 
that if a patient tests positive, the treatment should not be started unless the expected 
benefit clearly outweighs the risk of these events ever developing from 
carbamazepine.11 
Currently, Mission Health does not have a policy to address the use of carbamazepine 
in regards to the 2007 FDA warning or the CPIC guidelines and recommendations. This 
project provides the data necessary to guide a protocol for pre-carbamazepine 
genotype testing and/or developing a policy to offer alternative therapies at Mission 
Health to patients of Asian and Pacific Islander descent.   
Methods 
Study Design  
The study was a retrospective chart review, in which pre-recorded data was collected 
from patient medical records to characterize the use of carbamazepine at Mission 
Health. Medical records were abstracted for eligible patients.  This included both 
inpatients Mission Hospital and ambulatory patients at Mission Neurology between 2008 
and 2014 who were prescribed and administered carbamazepine and who were at least 
18 years or older.  Patients identified with at-risk genetic backgrounds, Asian or Pacific 
Islander, received further chart review.  A secondary query was done for inpatients at 
Mission Hospital, which involved searching medical records for patients with ICD-9 
codes associated with SJS/TEN reactions, 695.10, 695.12, 695.13, 695.14, 695.15, 
695.19 and the administration of carbamazepine plus other medications associated with 
hypersensitivity responses.  
The secondary query for SJS/TEN reactions included documentation of medications 
received during stay, as well as home medications. A manual review of drugs of interest 
was conducted, looking for drugs known to be associated with these reactions including: 
carbamazepine, oxcarbamazepine, phenytoin, abacavir, allopurinol, 
amoxicillin/clavulanate, sulfamethoxazole/trimethoprim, efavirenz, hydralazine, 
lamotrigine, nevirapine, and nonsteroidal anti-inflammatory medications (NSAIDs). The 
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reasoning behind conducting the secondary query was to determine whether any 
identified cases of SJS/TEN occurred in a patient of Asian or Pacific Islander descent.  
Also, the sencondary query was meant to be hypothesis generating, leading to further 
studies regarding drug-induced incidences of SJS/TEN reactions at Mission Health.  
The Mission Health Institutional Review Board approved all study procedures.   
Mission Health, based in Asheville, NC is a large, community, not-for-profit health 
system, including 6 hospitals, numerous outpatient and surgery centers, home health 
providers, and the region’s only level II trauma center, Mission Hospital. Mission 
Hospital is a ~750 bed hospital, serving largely a rural and underserved population 
within 19 counties of Western North Carolina. Although this region is mainly European 
American (89.7% Caucasian), as a tourist town and retirement location, there is 
potential for increased growth in the Asian population is predicted over the next several 
years. In addition, Western North Carolina has a growing Russian/Ukrainian population 
whose allele frequencies are largely unknown.   
Study Outcomes 
Queried data included the following clinical and demographic variables to characterize 
carbamazepine use:  date of visit, date prescribed carbamazepine, clinic location, 
primary health insurance plan, race or ethnicity, sex, age, ICD9 diagnosis code, 
allergies, other medications, and ICD9 codes associated with adverse drug events. 
Reviewing medical records from Mission Neurology and Mission Hospital provided the 
assessment of the frequency with which carbamazepine is being used, the dose and the 
condition it is being used to treat; the frequency with which Asian patients (especially 
Han Chinese descent or Indian Asians) have been prescribed and/or discharged with 
carbamazepine; the frequency with which patients have been hospitalized for SJS or 
NET or similar cutaneous skin lesions that might be associated with “culprit” drug use 
(e.g. carbamazepine).   
Results 
At the ambulatory outpatient clinic, Mission Neurology, data was collected from 
November 3rd, 2010 and September 29th, 2014. During that time, a total of 180 patients 
were prescribed carbamazepine. Of those patients, 165 were Caucasian, 2 American 
Indian, 1 Asian, 1 African American, and 11 were of unknown ancestry. These results 
can be seen in table 2. The study population included 58% female patients (n=105). 
Upon chart review of the Asian patients, no evidence of SJS/TEN reactions was seen. 
 
At the inpatient hospital facility, Mission Hospital, between 2008 and 2014, a total of 
2,407 individual patients were administered carbamazepine. Of those patients, 1,823 
were Caucasian, 105 African American, 17 American Indian, 4 Pacific Islander, 4 Asian, 
and 449 patients were of unknown ancestry. These results can be seen in table 3. The 
study population included 58% female patients (n=1385). Upon chart review of Asian 
and Pacific Islander patients, no evidence of SJS/TEN reactions was seen.  
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American Indian 2 
Asian 1 
African American  1 
Unknown 11 
Total 180 patients 
 




African American 105 
American Indian 17 
Hispanic or Latino 5 
Pacific Islander 4 
Asian 4 
Unknown 449 
Total 2,407 patients 
 
The secondary query demonstrated that between 2008 and 2014 at Mission Hospital, 
there were 72 incidences of erythema multiforme rash, SJS, or TEN, in 62 unique 
patients. Of these patients, 50 were Caucasian, 9 African American, 1 Hispanic, and 1 
patient of unknown ancestry as seen in table 4. Table 5 details specific medications 
these patients were taking that are known to be associated with these reactions, some 
of which having known pharmacogenomics predictor value.  
 
Table 4: Frequency of SJS/TEN 
Race Frequency 
Caucasian 50 
African American 9 
Hispanic 1 
Unknown 1 
Total 62 patients 
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Table 5: Medications of Interest in Patients with SJS/TEN 
Drugs Frequency ( # of patients)  
NSAIDs 40  
sulfamethoxazole/trimethoprim 17 
lamotrigine* 9 











For safety and quality issues, it is paramount that Mission Hospital addresses the 2007 
FDA Black Box Warning on Carbamazepine. The data from this study is helping to 
inform the development of practice policy to appropriately address the use of 
carbamazepine in genetically at-risk groups at Mission Health, those of Asian and 
Pacific Islander descent, thereby preventing the risk of serious adverse drug events. 
 
The results of this study demonstrate that at-risk patients have received carbamazepine 
at Mission Health between 2008 and 2014. Although, no incidences of SJS/TEN were 
seen in these patients, the genetic predisposition of the HLA-B*1502 allele to 
carbamazepine-induced SJS/TEN in Han Chinese patients is the strongest HLA-
disease association reported thus far. Because at-risk patients have received the drug, 
a protocol should be implemented.6 This data will serve to support the consideration of 
a policy change at Mission Hospital. Currently a proposal to develop an electronic 
warning as an Alert Trigger, or “pop-up” in the electronic medical record when 
carbamazepine (brand or generic) medication AND race = Asian OR Pacific Islander is 
being drafted. The warning message would suggest alternative medications for the 
genetically at-risk patient, or provide the clinician the ability to order the genetic test 
prior to drug use.   
 
In this study, we also identified that 19% (n=449) of patients who received 
carbamazepine at Mission Hospital between 2008 and 2014 were missing race 
information in their medical record. This gap of information included patients that 
refused to give race, as well as data that were just not collected. If we assume that one 
in five patients at Mission Hospital have unknown races at Mission Hospital, this is an 
area of considerable concern regarding patient safety in the light of the strung 
association between ancestry and genetic variations in drug response. In addition, it 
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would be a significant barrier to the implementation of clinical pharmacogenomics 
initiatives at Mission Health.   
 
This study has several limitations. The sample size of at-risk patients is small. This 
study also is limited regionally, and the results cannot necessarily be applied to different 
areas or medical centers. Larger medical centers in more diverse areas may have more 
compelling reasons to address this population-specific adverse event. Nonetheless, this 
research project has provided the evidence to support a policy change at Mission 
Health. In addition, as part of the study, a proposal was drafted for policy change, which 
is now being finalized through clinical pharmacists and submitted to Pharmacy and 
Therapeutics Committee at Mission Health.  
 
This research study will directly lead to a proposal for practice change at Mission Health 
regarding the use of carbamazepine in high-risk populations, also generating further 
awareness related to the implementation of pharmacogenomics testing at Mission 
Health. This study also demonstrates that there is a large rate of SJS/TEN reactions in 
other populations at Mission Hospital, with 72 incidences between 2008 and 2014, and 
that there may be possible drug/pharmacogenomics implications. Future research is 
needed to address the biologic basis of these observations, their clinical impact, and 
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